Sobi agreed to a $580 million deal involving Innate Pharma’s lacutamab program, securing rights to market the anti-KIR3DL2 antibody for an aggressive skin cancer. The arrangement includes $75 million upfront for Innate and additional economics tied to downstream milestones as development advances. The transaction sets up a clearer read on how antibody makers are repositioning rare oncology assets toward commercial-ready indications. Lacutamab is aimed at modulating NK and immune pathways, with Sobi positioning the asset as part of its strategy for difficult-to-treat diseases. For Innate, the partnership provides funding headroom as it focuses on its remaining portfolio. For Sobi and investors, the deal expands the company’s dermatology and oncology franchise beyond earlier commitments. The structure also signals that market participants see value in immune checkpoint-adjacent approaches that target specific immune receptor biology rather than broad checkpoint inhibition.